Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy

British Journal of Pharmacology

Volumn 172, Issue 12, 2015, Pages 3177-3188

  Citraro, Rita ^a   Leo, Antonio ^a   De Fazio, Pasquale ^a   De Sarro, Giovambattista ^a   Russo, Emilio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; FLUOXETINE; HALOPERIDOL; QUETIAPINE; RISPERIDONE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ABSENCE; ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; FORCED SWIM TEST; IMMOBILITY; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT DURATION; WISTAR ALBINO GLAXO RAT; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; EPILEPSY, ABSENCE; PSYCHOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; EPILEPSY, ABSENCE; MALE; RATS;

EID: 84930195257     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13121     Document Type: Article

References (98)

1. Ahern TH, Javors MA, Eagles DA, Martillotti J, Mitchell HA, Liles LC, et al. (2006). The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice. Neuropsychopharmacology 31: 730-738.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013) The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Bagdy G, Kecskemeti V, Riba P, Jakus R, (2007). Serotonin and epilepsy. J Neurochem 100: 857-873.
4. Berg AT, Levy SR, Testa FM, Blumenfeld H, (2014). Long-term seizure remission in childhood absence epilepsy: might initial treatment matter? Epilepsia 55: 551-557.
5. Blumenfeld H, Klein JP, Schridde U, Vestal M, Rice T, Khera DS, et al. (2008). Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia 49: 400-409.
6. Boyer EW, Shannon M, (2005). The serotonin syndrome. N Engl J Med 352: 1112-1120.
7. Brooks-Kayal AR, Bath KG, Berg AT, Galanopoulou AS, Holmes GL, Jensen FE, et al. (2013). Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 54 (Suppl. 4): 44-60.
8. de Bruin NM, van Luijtelaar EL, Jansen SJ, Cools AR, Ellenbroek BA, (2000). Dopamine characteristics in different rat genotypes: the relation to absence epilepsy. Neurosci Res 38: 165-173.
9. de Bruin NM, van Luijtelaar EL, Cools AR, Ellenbroek BA, (2001). Dopamine characteristics in rat genotypes with distinct susceptibility to epileptic activity: apomorphine-induced stereotyped gnawing and novelty/amphetamine-induced locomotor stimulation. Behav Pharmacol 12: 517-525.
10. Caplan R, Siddarth P, Stahl L, Lanphier E, Vona P, Gurbani S, et al. (2008). Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities. Epilepsia 49: 1838-1846.
11. Cardamone L, Salzberg MR, O'Brien TJ, Jones NC, (2013). Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol 168: 1531-1554.
12. Cavalheiro EA, Fernandes MJ, Turski L, Naffah-Mazzacoratti MG, (1994). Spontaneous recurrent seizures in rats: amino acid and monoamine determination in the hippocampus. Epilepsia 35: 1-11.
13. Cerullo MA, Strakowski SM, (2013). A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Spectr 18: 199-208.
14. Cheng YF, Paalzow LK, (1992). Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos 13: 69-76.
15. Citraro R, Scicchitano F, De Fazio S, Raggio R, Mainardi P, Perucca E, et al. (2011). Preclinical activity profile of alpha-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. Epilepsy Res 95: 60-69.
16. Citraro R, Russo E, Ngomba RT, Nicoletti F, Scicchitano F, Whalley BJ, et al. (2013a). CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. Epilepsy Res 106: 74-82.
17. Citraro R, Russo E, Scicchitano F, van Rijn CM, Cosco D, Avagliano C, et al. (2013b). Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-alpha receptor activation in a genetic model of absence epilepsy. Neuropharmacology 69: 115-126.
18. Citraro R, Chimirri S, Aiello R, Gallelli L, Trimboli F, Britti D, et al. (2014). Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. Epilepsia 55: 1284-1291.
19. Citraro R, Leo A, Aiello R, Pugliese M, Russo E, De Sarro G, (2015). Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats. Neurother 12: 250-262.
20. Ciumas C, Wahlin TB, Jucaite A, Lindstrom P, Halldin C, Savic I, (2008). Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy. Neurology 71: 788-794.
21. Correll CU, Kane JM, (2014). Schizophrenia: mechanism of action of current and novel treatments. J Clin Psychiatry 75: 347-348.
22. Deransart C, Riban V, Le B, Marescaux C, Depaulis A, (2000). Dopamine in the striatum modulates seizures in a genetic model of absence epilepsy in the rat. Neuroscience 100: 335-344.
23. Deransart C, Landwehrmeyer GB, Feuerstein TJ, Lucking CH, (2001). Up-regulation of D3 dopaminergic receptor mRNA in the core of the nucleus accumbens accompanies the development of seizures in a genetic model of absence-epilepsy in the rat. Brain Res Mol Brain Res 94: 166-177.
24. Dezsi G, Ozturk E, Stanic D, Powell KL, Blumenfeld H, O'Brien TJ, et al. (2013). Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy. Epilepsia 54: 635-643.
25. Dobryakova YV, Dubynin VA, Luijtelaar G, (2011). The effect of haloperidol on maternal behavior in WAG/Rij rats and its consequences in the offspring. Acta Neurobiol Exp (Wars) 71: 339-347.
26. Favale E, Audenino D, Cocito L, Albano C, (2003). The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 12: 316-318.
27. Filakovszky J, Gerber K, Bagdy G, (1999). A serotonin-1A receptor agonist and an N-methyl-D-aspartate receptor antagonist oppose each others effects in a genetic rat epilepsy model. Neurosci Lett 261: 89-92.
28. Gerber K, Filakovszky J, Halasz P, Bagdy G, (1998). The 5-HT1A agonist 8-OH-DPAT increases the number of spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res 807: 243-245.
29. Giblin KA, Blumenfeld H, (2010). Is epilepsy a preventable disorder? New evidence from animal models. Neuroscientist 16: 253-275.
30. Giorgi FS, Pizzanelli C, Biagioni F, Murri L, Fornai F, (2004). The role of norepinephrine in epilepsy: from the bench to the bedside. Neurosci Biobehav Rev 28: 507-524.
31. Graf M, Jakus R, Kantor S, Levay G, Bagdy G, (2004). Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy. Neurosci Lett 359: 45-48.
32. Hamid H, Kanner AM, (2013). Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs? Epilepsy Behav 26: 261-265.
33. Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA, (2012). Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 72: 184-191.
34. Hoppe C, Elger CE, (2011). Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol 7: 462-472.
35. Igelstrom KM, (2012). Preclinical antiepileptic actions of selective serotonin reuptake inhibitors-implications for clinical trial design. Epilepsia 53: 596-605.
36. Itil TM, Soldatos C, (1980). Epileptogenic side effects of psychotropic drugs. Practical recommendations. JAMA 244: 1460-1463.
37. Jakus R, Graf M, Juhasz G, Gerber K, Levay G, Halasz P, et al. (2003). 5-HT2C receptors inhibit and 5-HT1A receptors activate the generation of spike-wave discharges in a genetic rat model of absence epilepsy. Exp Neurol 184: 964-972.
38. Kanner AM, (2005). Should neurologists be trained to recognize and treat comorbid depression of neurologic disorders? Yes. Epilepsy Behav 6: 303-311.
39. Kanner AM, (2011). Depression and epilepsy: a bidirectional relation? Epilepsia 52 (Suppl. 1): 21-27.
40. Kanner AM, (2012). Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol 11: 1093-1102.
41. Kanner AM, Schachter SC, Barry JJ, Hesdorffer DC, Mula M, Trimble M, et al. (2012). Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav 24: 156-168.
42. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN, (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305: 625-631.
43. Kerr MP, Mensah S, Besag F, de Toffol B, Ettinger A, Kanemoto K, et al. (2011). International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 52: 2133-2138.
44. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
45. Lazarova M, Bendotti C, Samanin R, (1983). The role of different types of adrenergic receptors in pentylenetetrazol-induced seizures and the effect of di-n-propylacetate in the rat. Psychopharmacology (Berl) 81: 177-182.
46. Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, Garcia M, Aguirre C, (2013). Antipsychotics and seizures: higher risk with atypicals? Seizure 22: 141-143.
47. Li Y, Raaby KF, Sanchez C, Gulinello M, (2013). Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res 256: 520-528.
48. Lopez-Rubalcava C, Lucki I, (2000). Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test. Neuropsychopharmacology 22: 191-199.
49. van Luijtelaar G, Zobeiri M, (2014). Progress and outlooks in a genetic absence epilepsy model (WAG/Rij). Curr Med Chem 21: 704-721.
50. van Luijtelaar G, Sitnikova E, Littjohann A, (2011). On the origin and suddenness of absences in genetic absence models. Clin EEG Neurosci 42: 83-97.
51. van Luijtelaar G, Onat FY, Gallagher MJ, (2014). Animal models of absence epilepsies: what do they model and do sex and sex hormones matter? Neurobiol Dis 72 (Pt B): 167-179.
52. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, A Gray N, et al. (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53: 707-742.
53. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
54. McNamara RK, Able JA, Liu Y, Jandacek R, Rider T, Tso P, et al. (2013). Omega-3 fatty acid deficiency does not alter the effects of chronic fluoxetine treatment on central serotonin turnover or behavior in the forced swim test in female rats. Pharmacol Biochem Behav 114-115: 1-8.
55. Midzianovskaia IS, Kuznetsova GD, Coenen AM, Spiridonov AM, van Luijtelaar EL, (2001). Electrophysiological and pharmacological characteristics of two types of spike-wave discharges in WAG/Rij rats. Brain Res 911: 62-70.
56. Mishra PK, Burger RL, Bettendorf AF, Browning RA, Jobe PC, (1994). Role of norepinephrine in forebrain and brainstem seizures: chemical lesioning of locus ceruleus with DSP4. Exp Neurol 125: 58-64.
57. Nemeroff CB, Kinkead B, Goldstein J, (2002). Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63 (Suppl. 13): 5-11.
58. Nestler EJ, Hyman SE, (2010). Animal models of neuropsychiatric disorders. Nat Neurosci 13: 1161-1169.
59. Norman TR, Gupta RK, Burrows GD, Parker G, Judd FK, (1993). Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Psychopharmacol 8: 25-29.
60. Pape HC, McCormick DA, (1989). Noradrenaline and serotonin selectively modulate thalamic burst firing by enhancing a hyperpolarization-activated cation current. Nature 340: 715-718.
61. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR. (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
62. Perucca E, (2001). The management of refractory idiopathic epilepsies. Epilepsia 42 (Suppl. 3): 31-35.
63. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R, (2002). Effects of psychotropic drugs on seizure threshold. Drug Saf 25: 91-110.
64. Pitkanen A, Engel J Jr, (2014). Past and present definitions of epileptogenesis and its biomarkers. Neurother 11: 231-241.
65. Pitkanen A, Nehlig A, Brooks-Kayal AR, Dudek FE, Friedman D, Galanopoulou AS, et al. (2013). Issues related to development of antiepileptogenic therapies. Epilepsia 54 (Suppl. 4): 35-43.
66. Prendiville S, Gale K, (1993). Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia 34: 381-384.
67. Rai D, Kerr MP, McManus S, Jordanova V, Lewis G, Brugha TS, (2012). Epilepsy and psychiatric comorbidity: a nationally representative population-based study. Epilepsia 53: 1095-1103.
68. Reneric JP, Lucki I, (1998). Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 136: 190-197.
69. Richerson GB, Buchanan GF, (2011). The serotonin axis: shared mechanisms in seizures, depression, and SUDEP. Epilepsia 52 (Suppl. 1): 28-38.
70. Russo E, Citraro R, Scicchitano F, De Fazio S, Di Paola ED, Constanti A, et al. (2010). Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. Epilepsia 51: 1560-1569.
71. Russo E, Citraro R, Scicchitano F, De Fazio S, Perrotta I, Di Paola ED, et al. (2011a). Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia 52: 1341-1350.
72. Russo E, Citraro R, Scicchitano F, Urzino A, Marra R, Rispoli V, et al. (2011b). Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. Behav Brain Res 225: 373-376.
73. Russo E, Scicchitano F, Citraro R, Aiello R, Camastra C, Mainardi P, et al. (2012). Protective activity of alpha-lactoalbumin (ALAC), a whey protein rich in tryptophan, in rodent models of epileptogenesis. Neuroscience 226: 282-288.
74. Russo E, Citraro R, Davoli A, Gallelli L, Di Paola ED, De Sarro G, (2013a). Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 64: 371-379.
75. Russo E, Citraro R, Donato G, Camastra C, Iuliano R, Cuzzocrea S, et al. (2013b). mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 69: 25-36.
76. Sander T, Berlin W, Ostapowicz A, Samochowiec J, Gscheidel N, Hoehe MR, (2000). Variation of the genes encoding the human glutamate EAAT2, serotonin and dopamine transporters and Susceptibility to idiopathic generalized epilepsy. Epilepsy Res 41: 75-81.
77. Sankar R, Mazarati A, (2012). Neurobiology of depression as a comorbidity of epilepsy. In:, Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, (eds). Jasper's Basic Mechanisms of the Epilepsies, 4th edn. Oxford University Press: Bethesda, MD.
78. Sarkisova K, Folomkina AA, (2010). [Effect of selective serotonin reuptake inhibitor fluoxetine on symptoms of depression-like behavior in WAG/Rij rats]. Zh Vyssh Nerv Deiat Im I P Pavlova 60: 98-108.
79. Sarkisova K, van Luijtelaar G, (2011). The WAG/Rij strain: a genetic animal model of absence epilepsy with comorbidity of depression [corrected]. Prog Neuropsychopharmacol Biol Psychiatry 35: 854-876.
80. Sarkisova K, Kulikov MA, Kudrin VS, Narkevich VB, Midzianovskaia IS, Biriukova LM, et al. (2013). [Neurochemical mechanisms of depression-like behavior in WAG/Rij rats]. Zh Vyssh Nerv Deiat Im I P Pavlova 63: 303-315.
81. Sarkisova KY, Midzianovskaia IS, Kulikov MA, (2003). Depressive-like behavioral alterations and c-fos expression in the dopaminergic brain regions in WAG/Rij rats with genetic absence epilepsy. Behav Brain Res 144: 211-226.
82. Sarkisova KY, Kulikov MA, Midzyanovskaya IS, Folomkina AA, (2008). Dopamine-dependent nature of depression-like behavior in WAG/Rij rats with genetic absence epilepsy. Neurosci Behav Physiol 38: 119-128.
83. Sarkisova KY, Kuznetsova GD, Kulikov MA, van Luijtelaar G, (2010). Spike-wave discharges are necessary for the expression of behavioral depression-like symptoms. Epilepsia 51: 146-160.
84. Savic I, Lindstrom P, Gulyas B, Halldin C, Andree B, Farde L, (2004). Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology 62: 1343-1351.
85. Schmitt U, Dahmen N, Fischer V, Weigmann H, Rao ML, Reuss S, et al. (1999). Chronic oral haloperidol and clozapine in rats: a behavioral evaluation. Neuropsychobiology 39: 86-91.
86. Statnick MA, Dailey JW, Jobe PC, Browning RA, (1996a). Abnormalities in 5-HT1A and 5-HT1B receptor binding in severe-seizure genetically epilepsy-prone rats (GEPR-9s). Neuropharmacology 35: 111-118.
87. Statnick MA, Maring-Smith ML, Clough RW, Wang C, Dailey JW, Jobe PC, et al. (1996b). Effect of 5,7-dihydroxytryptamine on audiogenic seizures in genetically epilepsy-prone rats. Life Sci 59: 1763-1771.
88. Stefulj J, Bordukalo-Niksic T, Hecimovic H, Demarin V, Jernej B, (2010). Epilepsy and serotonin (5-HT): variations of 5-HT-related genes in temporal lobe epilepsy. Neurosci Lett 478: 29-31.
89. Trindade-Filho EM, de Castro-Neto EF, de A Carvalho RR, Lima E, Scorza FA, Amado D, et al. (2008). Serotonin depletion effects on the pilocarpine model of epilepsy. Epilepsy Res 82: 194-199.
90. Vega C, Vestal M, DeSalvo M, Berman R, Chung M, Blumenfeld H, et al. (2010). Differentiation of attention-related problems in childhood absence epilepsy. Epilepsy Behav 19: 82-85.
91. Volonteri LS, Colasanti A, Cerveri G, Fiorentini A, De Gaspari IF, Mauri MC, et al. (2010). Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels. J Psychopharmacol 24: 1193-1199.
92. Warter JM, Vergnes M, Depaulis A, Tranchant C, Rumbach L, Micheletti G, et al. (1988). Effects of drugs affecting dopaminergic neurotransmission in rats with spontaneous petit mal-like seizures. Neuropharmacology 27: 269-274.
93. Weinshenker D, Szot P, (2002). The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacol Ther 94: 213-233.
94. White HS, Loscher W, (2014). Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies. Neurother 11: 373-384.
95. Wong DT, (1998). Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Expert Opin Investig Drugs 7: 1691-1699.
96. Yan QS, Jobe PC, Cheong JH, Ko KH, Dailey JW, (1994a). Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Naunyn Schmiedebergs Arch Pharmacol 350: 149-152.
97. Yan QS, Jobe PC, Dailey JW, (1994b). Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Eur J Pharmacol 252: 105-112.
98. Yan QS, Dailey JW, Steenbergen JL, Jobe PC, (1998). Anticonvulsant effect of enhancement of noradrenergic transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): a microinjection study. Brain Res 780: 199-209.